Efficacy and Safety of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis

PHASE3CompletedINTERVENTIONAL
Enrollment

332

Participants

Timeline

Start Date

February 5, 2022

Primary Completion Date

July 17, 2022

Study Completion Date

July 17, 2022

Conditions
Strongyloides Stercoralis Infection
Interventions
DRUG

Moxidectin 2 mg

Monotherapy, oral administration, single-dose, fixed-dose, 4 tablets of 2 mg each to yield an 8 mg final dose.

DRUG

Ivermectin 3 mg

Monotherapy, oral administration, single-dose, weight dependent, The number of tablets will be adjusted according to the patients' weight to yield 200 ug/kg final dose.

DRUG

Placebo

Monotherapy, oral administration, single dose, matching number of tablets to either moxidectin or ivermectin

Trial Locations (1)

Unknown

National Centre for Parasitology, Entomology and Malaria Control, Phnom Penh

All Listed Sponsors
collaborator

National Centre for Parasitology, Entomology and Malaria Control, Cambodia

OTHER

lead

Jennifer Keiser

OTHER